Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)

Part of paid clinical trials in East Hanover, New Jersey.

Sponsor
Novartis Pharmaceuticals
Study ID
NCT05320159
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • Secukinumab — DRUG
    Included all the patients treated with secukinumab

Study Details

This was a retrospective cohort study utilizing data from Modernizing Medicine Data Services' (MMDS) electronic medical records (EMR)-based dermatology database to evaluate secukinumab patient characteristics, treatment patterns, and outcomes.

Key Dates

Start date
Feb 3, 2021
Status verified
Jun 2022
Primary completion
Mar 31, 2021
Completion
Mar 31, 2021

Study Design

Enrollment
17,743 participants (actual)

Arms

  • Arm: Overall cohort: Secukinumab
    Included all the patients treated with secukinumab
  • Arm: Bio-naive
    Included PsO patients initiating treatment with secukinumab. Bio-naïve was defined as no observed treatment (i.e., injection, prescription or patient reported history) with any of the following biologic drugs of interest anytime pre-index: secukinumab, certolizumab, etanercept, adalimumab, infliximab, golimumab, ustekinumab, ixekizumab, brodalumab, abatacept, and guselkumab and risankizumab during all available history
  • Arm: Bio-experienced
    Included PsO patients initiating treatment with secukinumab. Patients had pre-index use of one or more of the biologic drugs of interest during all available history
  • Arm: Systemic-naive
    Included PsO patients initiating treatment with secukinumab. Systemic-naïve was defined as no observed treatment (i.e., injection, prescription or patient reported history) with any of the biologic treatments or with any of the following systemic (i.e., oral or injectable - no topical forms) drugs of interest pre-index: methotrexate, corticosteroids, acitretin or apremilast.
  • Arm: Systemic-experienced
    Included PsO patients initiating treatment with secukinumab. Systemic-experienced patients had pre-index use of one or more of the systemic drugs of interest.

Primary Outcome Measure

Treatment satisfaction level at Baseline [ Time Frame: Baseline ]

Locations (1)

FacilityCityStateZIPSite coordinators
Novartis Investigative SiteEast HanoverNew Jersey07936-1080-

Find similar trials in East Hanover, NJ

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Novartis Investigative Site· East Hanover, NJ

Related Studies